VBI Vaccines Inc. (VBIV)
Market Cap | 20.39M |
Revenue (ttm) | 9.41M |
Net Income (ttm) | -83.99M |
Shares Out | 28.68M |
EPS (ttm) | -5.65 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 383,350 |
Open | 0.700 |
Previous Close | 0.692 |
Day's Range | 0.685 - 0.780 |
52-Week Range | 0.450 - 2.680 |
Beta | 1.99 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 12, 2024 |
About VBIV
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops ... [Read more]
Financial Performance
In 2023, VBI Vaccines's revenue was $8.68 million, an increase of 702.40% compared to the previous year's $1.08 million. Losses were -$93.84 million, -17.18% less than in 2022.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/k/o/press2-2496236.jpg)
VBI Vaccines Announces Results of Annual General Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of di...
![](https://cdn.snapi.dev/images/v1/6/f/press18-2451390.jpg)
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...
![](https://cdn.snapi.dev/images/v1/g/i/press11-2443242.jpg)
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...
![](https://cdn.snapi.dev/images/v1/i/h/press20-2433263.jpg)
VBI Vaccines Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provid...
![](https://cdn.snapi.dev/images/v1/5/t/press14-2373321.jpg)
VBI Vaccines Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provid...
![](https://cdn.snapi.dev/images/v1/1/z/press6-2368140.jpg)
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...
![](https://cdn.snapi.dev/images/v1/z/h/press2-2363946.jpg)
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...
![](https://cdn.snapi.dev/images/v1/2/j/press19-2354027.jpg)
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...
![](https://cdn.snapi.dev/images/v1/v/l/press15-2351823.jpg)
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of di...
![](https://cdn.snapi.dev/images/v1/w/r/press2-2275349.jpg)
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of di...
![](https://cdn.snapi.dev/images/v1/6/h/press9-2274886.jpg)
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain activities Transferring manufacturing technol...
![](https://cdn.snapi.dev/images/v1/y/u/press17-2165096.jpg)
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...
![](https://cdn.snapi.dev/images/v1/t/p/press2-2157974.jpg)
VBI Vaccines Reports Third Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provid...
![](https://cdn.snapi.dev/images/v1/7/c/press13-2122507.jpg)
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...
![](https://cdn.snapi.dev/images/v1/y/g/im-851536size1777777777777778width800-2079524.jpg)
VBI Vaccines' pan-coronavirus vaccine candidate produced broad protection against variants of concern
VBI Vaccines Inc. said Wednesday the first clinical data from a Phase I trial of a pan-coronavirus vaccine candidate produced broad and durable protection against variants of concern.
![](https://cdn.snapi.dev/images/v1/g/h/press16-2079482.jpg)
VBI Vaccines' Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...
![](https://cdn.snapi.dev/images/v1/4/t/press6-2053428.jpg)
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...
![](https://cdn.snapi.dev/images/v1/e/t/press12-2051258.jpg)
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”) today announced that its strategic hepatitis B (HBV) partner, Brii Biosciences (Brii Bio) (Stock code: 2137...
![](https://cdn.snapi.dev/images/v1/h/f/press7-2050829.jpg)
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased HBsAg seroconversion rate is stro...
![](https://cdn.snapi.dev/images/v1/y/i/press6-2032491.jpg)
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
First patient dosed in a PEG-IFN -α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching pa...
![](https://cdn.snapi.dev/images/v1/q/n/press12-2021397.jpg)
VBI Vaccines Reports Second Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provid...
![](https://cdn.snapi.dev/images/v1/f/r/press14-1984094.jpg)
VBI Vaccines Announces Closing of Underwriters' Partial Exercise of Option to Purchase Additional Common Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of diseas...
![](https://cdn.snapi.dev/images/v1/u/l/press5-1977768.jpg)
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ...
![](https://cdn.snapi.dev/images/v1/t/p/press9-1960629.jpg)
VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of diseas...
![](https://cdn.snapi.dev/images/v1/n/o/press9-1959761.jpg)
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive ...